An interventional study of Usual Care Group and Controlled exercise with telerehabilitation in Morbid Obesity, Bariatric Surgery and Telerehabilitation, sponsored by Instituto de Investigacion Sanitaria La Fe. Recruiting at 2 sites in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Instituto de Investigacion Sanitaria La Fe · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Obesity, Morbid with a site in Spain — 11 open to participants now, 14 under way, 1 of them phase 3. Obesity, Morbid · Spain.
Among the 38 studies in Obesity, Morbid with a site in Spain, this one is the 12th largest by planned enrollment of the 25 interventional ones that give a count, is one of 3 that started in 2025, is one of 22 with no phase, reaches primary completion later than 11 of the 13 other live ones, and was the 34th registered.
941 studies on the registry are indexed under Obesity, Morbid; 162 are open to participants now.
Browse Obesity, Morbid studies →11 of the 38 studies in Obesity, Morbid with a site in Spain are open now. Recruiting first, the newest first:
Hospitales Universitarios Virgen del Rocío · Sites in Spain
Ages 18–74
Regeneron Pharmaceuticals · Sites in Spain, Germany, Turkey
Ages 2+
University of Alicante · Sites in Spain
Ages 18–70
Corporacion Parc Tauli · Sites in Spain
Ages 18–65
Institut de Recerca Biomèdica de Lleida · Sites in Spain
Ages 18–65
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 109 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 83 (76%) stop at 75 or younger; 8 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 72 is above the median of 62 across 601 interventional studies indexed under Obesity, Morbid.
Median enrollment 68 across the 25 interventional studies, 145 across the 13 observational. Of the 16 that completed or were terminated, 1 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 38 have an industry lead sponsor. The 10 most frequent:
Instituto de Investigacion Sanitaria La Fe is the lead sponsor of 58 studies on the registry; 12 are open to participants now.
Instituto de Investigacion Sanitaria La Fe has 1 study filed under Obesity, Morbid — fewer than ten, so there is no comparison to draw.
2 of the studies in Obesity, Morbid with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220772Phase 3Regeneron PharmaceuticalsA Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults | 2027-06-18 |
| NCT06226194Institut de Recerca Biomèdica de LleidaGenetic Susceptibility to Predict Weight Loss After Bariatric Surgery | 2027-03-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 38 studies in Obesity, Morbid with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial aims to determinate whether a structured exercise program, supported by telerehabilitation, can help individuals with severe obesity who are going to undergo bariatric surgery.
The main objective of this study is whether a structured exercise program, including both supervised and home-based workouts, leads to greater body fat loss and improved strength compared to usual care. Furthermore, it also aims to evaluate other potentially affected aspects, such as body composition and functionality, quality of life, cardiovascular fitness, and various genetic and metabolic factors.
This study is a randomized clinical trial with two groups:
The study will include 72 adults with severe obesity (36 men and 36 women), all of whom will be randomly assigned to either the intervention or control group.
Participants in the exercise group will follow these steps:
Participants in the exercise group will also receive the same care as the control group, including nutrition counseling and medical checkups.
To evaluate participant progress, a series of measurements will be carried out, including:
If proven effective, this program could help establish structured exercise with telerehabilitation as a standard component of obesity care. The results may support the integration of exercise programs into clinical practice, leading to improved long-term outcomes for individuals with severe obesity undergoing bariatric surgery. Additionally, insights into genetic and metabolic factors may contribute to the development of personalized treatment strategies.
INTRODUCTION Severe obesity represents a growing public health challenge in Spain, with a marked increase in prevalence and significant implications for morbidity, mortality, and healthcare expenditure. In 2022, nearly 400,000 individuals were affected by class III obesity, reflecting an increase of more than 200% since the 1990s. This condition is strongly associated with serious comorbidities, including cardiovascular disease, type 2 diabetes, and certain cancers, and is linked to a substantial reduction in life expectancy. From an economic perspective, overweight and obesity are estimated to account for approximately 10% of national healthcare costs, with severe obesity contributing significantly through both direct medical expenses and indirect costs related to productivity loss.
Conventional treatment strategies, such as dietary interventions and physical activity (PA), offer limited long-term effectiveness in individuals with severe obesity. Although physical exercise (PE)-a structured form of PA-has shown benefits beyond weight reduction, including improvements in body composition and cardiorespiratory fitness, the majority of participants find it difficult to sustain behavioral changes over time. Furthermore, the degree of weight loss required in this population frequently exceeds what lifestyle interventions alone can achieve.
Bariatric surgery has emerged as an effective alternative, providing substantial short-term weight reduction and improvement in obesity-related comorbidities. However, it is not without limitations, including the loss of lean body mass and the risk of long-term weight regain, particularly in the absence of adequate PA following surgery. Recent studies have shown that postoperative PE programs may improve these outcomes, although the evidence on the benefits of preoperative exercise (prehabilitation) remains limited.
In this context, telerehabilitation appears to be a promising strategy for enhancing accessibility, adherence, and continuity of care. Remote supervision of structured exercise programs, supported by wearable technologies such as activity trackers, may help overcome common barriers and increase participant engagement. Additionally, the substantial variability in individual responses to obesity treatment highlights the need for personalized interventions. Genetic, metabolic, and epigenetic factors likely contribute to treatment resistance in certain individuals, and the identification of predictive biomarkers may help guide more effective and individualized obesity management strategies.
OBJECTIVES:
Primary Objective To evaluate whether a structured PE and PA promotion program, incorporating both supervised in-person and home-based sessions through telerehabilitation tools, is more effective than standard care guidelines in reducing fat percentage and increasing lower-limb strength in candidates for bariatric surgery.
Secondary Objectives
To determine whether the structured PE and PA program is more effective than standard care in achieving:
Additional secondary objectives include:
METHODOLOGY The methodology of the study is included in the initial summary and detailed in the subsequent sections (study design, arms and interventions, outcomes measures and elegibility) .
SAMPLE SIZE The sample size for this clinical trial was determined based on the two coprimary outcomes: fat percentage and lower-limb strength. For fat percentage, the calculation aimed to detect a 2% reduction in the experimental group compared to the control group, with 80% statistical power and a 5% significance level, resulting in an estimated minimum of 13 participants per group. Similarly, for lower-limb strength, assessed via the 5-repetition Sit-to-Stand (5STS) test, a 30% improvement was considered clinically relevant, requiring only 6 participants per group under the same statistical assumptions.
Given that the variable with the higher sample size requirement was fat percentage, it was used to guide the final sample size. To allow for subgroup analyses by sex, the study was designed to include 30 participants per group-15 women and 15 men. To accommodate an anticipated dropout rate of 20%, the final sample size was increased to 36 participants in each group, with equal sex distribution (18 women and 18 men per group).
STATISTICAL METHODS Data management and statistical analyses will be performed using SPSS software. A dedicated study database will be created, and data accuracy will be verified through random cross-checks with original records. Prior to analysis, data cleaning will be conducted to ensure consistency and completeness, followed by the creation of derived variables where necessary.
The analysis will begin with a flowchart of participant progression throughout the study, alongside a comparison of baseline characteristics between groups to assess equivalence at enrollment. Descriptive statistics will be used: categorical variables will be reported as frequencies and percentages, while continuous variables will be expressed as means and standard deviations or medians and interquartile ranges, depending on data distribution.
To evaluate the primary outcomes, a mixed-model ANOVA will be conducted, with time (baseline, end of prehabilitation, and pre-surgery) as the within-subject factor and group allocation (intervention vs. control) as the between-subject factor. The assumptions of normality and homogeneity will be tested using the Shapiro-Wilk and Levene's tests, respectively. When assumptions are violated, appropriate statistical corrections will be applied.
Effect sizes will be reported using partial eta squared (η²), and post hoc analyses will include Bonferroni correction when significant group-time interactions are detected. The magnitude of observed effects will be interpreted using Cohen's d.
The same statistical approach will be applied to secondary outcomes, such as physical function, cardiovascular fitness, quality of life, and body composition. Intervention adherence will be quantified by the proportion of completed sessions and those performed at the prescribed intensity, followed by between-group comparisons using non-parametric tests as appropriate.
To assess the influence of fat mass reduction and improved lower-limb strength on clinically relevant outcomes (e.g., Six-Minute Walk Test [6MWT], Impact of Weight on Quality of Life [IWQOL]), participants will be dichotomized based on whether they achieved a minimally clinically important difference. Multivariate logistic regression models will be constructed, using these two variables and sex as predictors. Model refinement will be carried out via backward elimination, and results will be presented as odds ratios with 95% confidence intervals.
Finally, linear regression models will be used to explore associations between body composition and functional outcomes with genetic, metabolic, and epigenetic markers.
SUBSTUDY 2: POSTOPERATIVE REHABILITATION FOLLOWING BARIATRIC SURGERY In addition to the main study, a subgroup of participants will be enrolled exclusively in the postoperative phase, forming part of Substudy 2. This substudy targets individuals already on the bariatric surgery waiting list and focuses solely on postoperative rehabilitation and maintenance.
The study design and intervention protocols are identical to those of the main study, but the follow-up period is limited to 12 months. Measurements will be conducted at three time points: prior to surgery, 6 months post-surgery, and 12 months post-surgery.
The key differences between the two substudies are as follows:
Primary Outcome Measures: Given the exclusive postoperative focus of Substudy 2, the primary endpoints differ from those in the main study:
To allow for sex-based subgroup analyses, each group (intervention and control) must include 30 participants-15 women and 15 men. Considering an expected dropout rate of approximately 15% in this substudy, the final sample size will be increased to 34 participants per group, resulting in a total of 68 participants overall.
Aside from the differences outlined above, all remaining aspects of Substudy 2-including methodology, intervention content, and assessment procedures-will follow the same protocols described in the main study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will engage in structured physical exercises, including both aerobic and strength training, guided and monitored by physiotherapists. These exercises will be performed both in person and remotely with the support of telerehabilitation.
Behavioral: Controlled exercise with telerehabilitation
Participants will receive the usual dietary and physical activity recommendations during medical assessments and group sessions.
Behavioral: Usual Care Group
Participants will receive the standard intervention provided by the healthcare service, which includes recommendations for physical exercise, physical activity, and healthy eating. This intervention is delivered by the Endocrinology and Nutrition Department at Hospital Universitario y Politécnico La Fe and consists of periodic individual follow-ups (at least three in-person visits per year, both pre- and post-bariatric surgery) by specialized medical staff in Endocrinology and licensed Nutrition and Dietetics professionals. Additionally, it includes five preoperative group sessions focusing on various aspects of healthy nutrition, physical exercise, and physical activity.
Participants will receive the same standard care as the control group, including the same number of visits with the physician and nutritionist and participation in group sessions. Additionally, they will follow a structured physical exercise program, tailored to individual capabilities, combining aerobic and strength exercises, which will primarily be carried out at home with the assistance of telerehabilitation. Physical exercise will be structured in different phases: prior to surgery (prehabilitation), after surgery (rehabilitation), with maintenance periods in between.
Fat mass percentage
The percentage of fat mass relative to the patient's total body mass, measured using bioelectrical impedance analysis (BIA).
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Lower limb strength
Measured by the 5 repetitions Sit-To-Stand test (5STS)
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Weight
Measured with BIA machine. Units: kilograms
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Height
Measured using a stadiometer permanently fixed to a wall to minimize variability between patients. Units: meters
Time frame: Baseline
Waist circumference
Measured with a non-elastic tape measure. Units: centimeters
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Skeletal muscle mass
Measured using bioelectrical impedance analysis (BIA).
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Lean body mass
Measured using bioelectrical impedance analysis (BIA).
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Visceral fat area
Measured using bioelectrical impedance analysis (BIA).
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Blood preasure
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Isometric muscle strength
Measured with hand grip, knee extension and elbow flexion. Units: kilograms
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
6 minutes walking test (6MWT)
The 6WMT measures the distance the patient travels in 6 minutes walking as fast as they can. The total distance walked is recorded in meters. The greater the distance, the better the results.
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Short Performance Physical Battery (SPPB)
The SPPB consists of three components: * Balance tests:: The participant is asked to maintain balance in three positions: side-by-side stance, semi-tandem stance, and full tandem stance, each for up to 10 seconds. * Speed test: The time taken to walk 4 meters * Chair stand test: The participant is instructed to stand up and sit down from a chair five times as quickly as possible without using their arms. The time taken is recorded. Each component is scored from 0 to 4 points, with a maximum total score of 12. Higher scores indicate better physical performance. The SPPB is widely used in clinical and research settings for assessing frailty, risk of disability, and physical function.
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
VO2max/VO2 peak
Estimated through 6MWT
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Steps per day
We will provide patients with pedometers to monitor their daily mobility.
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
International Physical Activity Questionnaire (IPAQ):
The IPAQ collects information on physical activity performed in the last 7 days across three specific types: walking, moderate-intensity activities and vigorous-intensity activities. Participants are asked to report the frequency (days per week) and duration (minutes per day) of each activity type. The questionnaire also includes a question on time spent sitting, to estimate sedentary behavior. Physical activity data are converted into Metabolic Equivalent of Task (MET)-minutes/week, allowing categorization of individuals into three levels of physical activity: low, moderate, or high.
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
International Sedentary Assessment Tool (ISAT)
Participants report the average amount of time spent in sedentary behaviors on a typical weekday and weekend day. The questions activities analyze the time spent sitting while doing some activities such as working, transportation, watching television or using screens.
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Short Form-36 Health Survey (SF-36)
It evaluates eight dimensions of health across physical and mental domains: Physical Function, Physical Role; Bodily Pain; General Health; Vitality; Social Function; Emotional Role and Mental Health. Each dimension is scored from 0 to 100, with higher scores indicating better health status.
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Impact of Weight on Quality of Life (IWQOL)
It evaluates the physical, emotional, and social impact of overweight and obesity on daily functioning and well-being. It's grouped into five domains: physical function, self-esteem, sexual life, public distress and work. Participants rate how true each statement is for them, using a 5-point scale. Minimum value: 31, Maximum value: 155 Higher scores indicate better weight-related quality of life.
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Bariatric Analysis and Reporting Outcome System (BAROS)
The BAROS assesses different aspects of patients undergoing bariatric surgery, including the percentage of excess weight lost, comorbidities and quality of life. Each domain is scored and higher scores indicate better outcomes. Minimum value: 0, Maximum value: 48
Time frame: 6 months post-surgery and one year post-surgery.
Number of participants with abnormal laboratory tests results
Several analytical parameters will be assessed in the participants, including complete blood count, biochemical analysis with electrolytes, renal and hepatic function, glycemic levels and HbA1c, albumin levels, vitamin profile, and markers of iron metabolism. Furthermore, the quantification of various exerkines, adipokines, and cytokines will also be conducted.
Time frame: Baseline, 6 months, perioperative, 6 moths after and 1 year after
Number of participants with genetic alterations
A genetic panel targeting obesity-related genes will be performed if funding is secured. Initially, the samples will be stored in a biobank. The following exons will be analyzed: ABCC8, ACBD6, ADCY3, ADRB2, AFF4, AKR1C2, ALMS1, ARL6, BBIP1, BBS1, BBS10, BBS12, BBS2, BBS4, BBS5, BBS7, BBS9, BDNF, CEL, CEP164, CEP19, CEP290, CPE, CREBBP, CUL4B, CYP27A1, DNMT3A, DYRK1B, EHMT1, EIF2AK3, ENPP1, EP300, FOXP3, FTO, GCK, GHRL, GLIS3, GNAS, GNB1, HNF1A, HNF1B, HNF4A, IFNGR1, IFT172, IFT27, IFT74, INPP5E, INS, KCNJ11, KDM6A, KIDINS220, KIF7, KMT2D, KSR2, LEP, LEPR, LZTFL1, MAGEL2, MC4R, MEGF8, MKKS, MKRN3, MKS1, MRAP2, MYT1L, NDN, NEUROD1, NEUROG3, NLGN2, NR0B2, NTRK2, P4HTM, PCSK1, PDE4D, PDX1, PGM2L1, PHF6, PHIP, POMC, PPARG, PRKAR1A, PRKN, PRMT7, PTF1A, RAB23, RAD21, RAI1, RFX6, RPS6KA3, SCAPER, SCLT1, SDCCAG8, SETD1B, SETD2, SH2B1, SIM1, SNRPN, STX16, TFAP2B, TMEM67, TRAPPC9, TRIM32, TTC8, TUB, VPS13B, WDPCP, WFS1.
Time frame: Baseline (Stored in a biobank for analysis if funding is obtained)
Not enrolling at this site.
Plan to share: No
Started May 2025 (actual). Primary completion is estimated for Dec 2028, 43 months after the start.
Of 273 non-industry interventional studies with no phase under Obesity, Morbid, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 48. This study's planned 43 months is above that.
Counting every sponsor, half of 285 studies reached it within 25 months; a quarter within 11 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto de Investigacion Sanitaria La Fe